Reported herein is the possible interaction between two drugs used to treat a man with a large prolactin-secreting pituitary adenoma. The patient had a long history of schizophrenia that was treated with many different medications, including phenothlazines. Evaluation of progressive lethargy led to the discovery of a large parasellar tumor and a prolactin level of 7,981 ng/ml. His serum prolactln level fell to the 400 ng/ml range during bromocriptine therapy but rose whenever the antipsychotic thioridazine was added to his regimen. A marked deterioration of his visual fields was noted after 3 months' therapy with both drugs, and this abnormality resolved five days after the thioridazine was stopped. The use of dopamlne antagonists such as thioridazine in patients with prolactinoma may interfere with bromocriptine's action, resulting in potentially serious complications.

Original languageEnglish
Pages (from-to)921-923
Number of pages3
JournalAmerican Journal of Medicine
Issue number5
StatePublished - May 1984

Bibliographical note

Funding Information:
From the Division of Endocrinology and Psychiatric Liaison Division, Departments of Medicine and Psychiatry, University of Colorado Health Sciences Center, Denver, Colorado. This work was supported in part by Sandoz, Inc., East Hanover, New Jersey. Requests for reprints should be addressed to Dr. Richard J. Robbins, Endocrine Division, 6151, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, Colorado 80262. Manuscript accepted June 14, 1983.

Copyright 2014 Elsevier B.V., All rights reserved.

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma'. Together they form a unique fingerprint.

Cite this